Chennai-based Orchid Pharmaceuticals has received the final approval from the United States Food and Drug Administration for Rasagiline generic formulation, which is used for the treatment of idiopathic Parkinson’s disease.
The company informed the Bombay Stock Exchange that the product is a first-to-file application with shared 180-day exclusivity for Orchid.
With the launch the new product between January and March 2017, the company hopes to garner decent market share in the generic drug market.